NCT01614899View on ClinicalTrials.gov

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

457

Participants

Timeline

Start Date

July 2, 2012

Primary Completion Date

November 17, 2014

Study Completion Date

November 17, 2014

Conditions
Schizophrenia
Interventions
DRUG

SM-13496 40mg

once daily orally

DRUG

SM-13496 80mg

once daily orally

DRUG

Placebo

once daily orally

Trial Locations (4)

Unknown

69 Sites, Tokyo, Etc

10 Sites, Kuala Lumpur, Etc

22 Sites, Seoul, Etc

14 Sites, Taipei, Etc

All Listed Sponsors
lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT01614899 - A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter